Novartis Investigative Site

Yotsukaidō, Chiba 284-0003

0 studies enrolling now · 1 studies all time

What they study most

Rheumatoid Arthritis

Studies at this site

• Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents — Completed